Sword Health's €34.6M Boost, RyboDyn's Immunotherapy Leap, and AI Innovations at HFMA 2025 - Life AI Weekly #23

Hi there,

Welcome to this week's edition of Life AI Weekly, where we delve into the latest advancements in AI within the healthcare and life sciences sectors. This week, we highlight several significant developments, including RyboDyn's collaboration with Lilly Gateway Labs to advance immunotherapy research. In the realm of business and investments, Sword Health has secured €34.6 million to expand its AI-driven mental health solutions, while HOPPR has raised $31.5 million to enhance AI applications in medical imaging.

Additionally, RevelAi Health has garnered $3.1 million to innovate AI in musculoskeletal care. On the technology front, Infinitus Systems is expanding its partnership with Salesforce, and The SSI Group has unveiled new AI solutions at the HFMA 2025 conference. Stay tuned as we explore these stories and their implications for the future of healthcare technology.

Sword Health has secured €34.6 million to expand its AI-driven mental health solution, Mind. HOPPR raised $31.5 million in Series A funding to enhance AI infrastructure for medical imaging. RevelAi Health obtained $3.1 million in seed funding to advance its AI platform for musculoskeletal care.

RyboDyn has joined Lilly Gateway Labs to advance its work in immunotherapy development.

RyboDyn joins Lilly Gateway Labs to advance immunotherapy development.

RyboDyn has been selected to join Lilly Gateway Labs to advance immunotherapy development targeting the dark proteome, leveraging Eli Lilly and Company's global scientific network.

Infinitus Systems, Inc. has expanded its partnership with Salesforce to enhance AI agent adoption in healthcare. The SSI Group, LLC unveiled new AI solutions for revenue cycle management at HFMA 2025.